drugset / Trial / NCT01592786
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify responders for participation in a follow-up randomized withdrawal study.
Timeline
- Start
- 2012-06
- Primary completion
- 2013-07
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Memantine | Unknown | 3 mg | Oral |
| Subject | Memantine | Unknown | 6 mg | Oral |
| Subject | Memantine | Unknown | 9 mg | Oral |
| Subject | Memantine | Unknown | 15 mg | Oral |